Overexpression of human ATP-binding cassette transporter ABCG2 in cancer cells causes multidrug resistance by effluxing anticancer drugs. ABCG2 is considered as a half transporter and is thought to function as a homodimer. However, recent evidence suggests that it may exist as a higher form of oligomer consisting of 12 subunits. In this study, we mapped the oligomerization domain of human ABCG2 to its transmembrane domain consisting of TM5-loop-TM6. This oligomerization domain, when expressed alone in HEK293 cells, also forms a homododecamer. Furthermore, this domain has activity that inhibits drug efflux and resistance function of the full-length ABCG2 likely by disrupting the formation of the homo-oligomeric full-length ABCG2. These findings suggest that human ABCG2 may exist and work as a homo-oligomer by interactions located in TM5-loop-TM6, and that ABCG2 oligomerization may be used as a target for therapeutic development to circumvent ABCG2-mediated drug resistance in cancer treatment. [Cancer Res 2007;67(9):4373-81] 
Introduction
Multidrug resistance is a serious problem in cancer chemotherapy. Overexpression of some members of the ATP-binding cassette (ABC) transporter superfamily causes increased efflux of anticancer drugs, resulting in decreased intracellular accumulation of anticancer drugs, and thus, the cancer cells can survive drug treatment (1) (2) (3) (4) (5) . ABCG2 is one example of these transporters that have been shown to cause increased drug efflux and resistance (6) (7) (8) (9) .
Unlike traditional full ABC transporters with two transmembrane domains (TMD) and two nucleotide binding domains (NBD), ABCG2 consists of only one NBD and one TMD, with a domain structure of NBD-TMD. It has been thought to exist and function as a homodimer covalently linked by disulfide bonds (10) (11) (12) in the third extracellular loop between TM5 and TM6 (13, 14) . However, it has been found recently that human ABCG2 exists in the drugresistant cells mostly as a higher form of oligomer containing 12 subunits with noncovalent interactions (15) .
In this study, we delineated the oligomerization domain of human ABCG2 and tested whether oligomerization could be exploited as a target for intervention of ABCG2-mediated drug resistance. We found that the domain consisting of TM5-loop-TM6 is responsible for ABCG2 oligomerization. Ectopically expressed TM5-loop-TM6 domain exists as a dodecamer, and its coexpression inhibits ABCG2-mediated drug efflux and resistance. These findings suggest that human ABCG2 likely exists and works as a homo-oligomer by interactions located in TM5-loop-TM6, and that ABCG2 oligomerization may be used as a target for therapeutic development to circumvent ABCG2-mediated drug resistance in cancer therapy.
Materials and Methods
Materials. Bxp-21 against ABCG2, anti-Myc and anti-HA antibodies, and protein G-Sepharose 4B were purchased from ID Labs, Cell Signaling, Covance, and Santa Cruz Biotechnology, respectively. G418, hygromycin, LipofectAMINE/Opti-MEM transfection reagents were from Invitrogen. pTK-Hyg plasmid, perfluoro-octanoic acid (PFO), protease inhibitor cocktail tablets, disuccinimidyl suberate (DSS) were from Clontech, Oakwood Products, Roche Diagnostics, and Pierce Biotechnology, respectively. N,Ndimethyl formamide, mitoxantrone, etoposide (VP-16), 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), and Triton X-100 were obtained from Sigma. Enhanced chemiluminescence reagents, Superdex 200 HR column, thyroglobulin, ovalbumin, and RNase A were from Amersham/ Pharmacia. Polyvinylidene difluoride membranes, protein concentration assay kit, and precast polyacrylamide gradient gels were from Bio-Rad. Cell culture media and reagents were obtained from either Invitrogen or Cambrex Bioscience. All other reagents of molecular biology grade were purchased from Sigma or Fisher.
Engineering of HA or Myc-tagged ABCG2 constructs. All truncated constructs were engineered by first performing a PCR to amplify the cDNA of interest using primers carrying BamHI or EcoRI site. The PCR products were then digested with BamHI and EcoRI and subsequently cloned into pcDNA3, resulting in final expression constructs. All final constructs were verified by double-strand DNA sequencing.
To engineer tagged NBD (ABCG2 Myc-NBD ) and TMD (ABCG2 TMD-HA ), we first analyzed the amino acid sequence of human ABCG2 and found a potential linker region between NBD and TMD, 78 amino acids downstream of the Walker B sequence similar as that in human ABCB1. We thus engineered these constructs by using this potential linker region as cleavage sites. ABCG2
Myc-NBD was produced by PCR using a Myc tag-encoding forward primer containing a BamHI site: 5 ¶-CGCGGATCCGCCGCCATGGAA-CAAAAGCTCATCTCAGAAGAAGATCTGTCTTCCAGTAATGTCGAAGTT-3 ¶ and a reverse primer containing an EcoRI site and a stop codon: 5 ¶-CCGGAATTCATCAATAAATCTCCGCTAATTTTTCTATGAGTGG-3 ¶. ABCG2
TMD-HA was produced by PCR using a forward primer containing a Bam HI site 5 ¶-CGCGGATCCGCCGCCATGAAGCCACTCATAGAAAAAT-TAGCGGAG-3 ¶ and an HA-encoding reverse primer containing an EcoRI site and a stop codon 5 ¶-CCGGAATTCATCAGCTAGCATAATCTGGGACGTCG-TATGGGTAAGAATATTTTTTAAGAAATAAC-3 ¶. ABCG2 Myc-TM1-2 and ABCG2 Myc-TM1-4 were cloned in the same way as ABCG2
Myc-NBD with a Myc tag-encoding forward primer containing a BamHI site: 5 ¶-CGCGGATCCGCCGCCATGGAACAAAAGCTCATCTCAGAAGAA-GATCTGTCTTCCAGTAATGTCGAAGTT-3 ¶ and reverse primers containing an EcoRI site and a stop codon: 5 ¶-CCGGAATTCATCACGTCATGGGTAA-TAAATCAGATAACAGTTT-3 ¶ ( for ABCG2
Myc-TM1-2 ) and 5 ¶-CCGGAATTCAT-CATACAGAAACCACACTCTGACCTGCTG C-3 ¶ ( for ABCG2
Myc-TM1-4 ).
ABCG2
Myc-TM5-6 was engineered using PCR with a Myc-tag-encoding forward primer containing a BamHI site 5 ¶-CGCGGATCCGCCGCCATG-G A A C A A A A G C T C A T C T C A G A A G A A G A T C T G G C A G C A G GT C A -GAGTGTGGTTTCTGTA-3 ¶ and a reverse primer containing an EcoRI site 5 ¶-CCGGAATTCATTAAGAATATTTTTTAAGAAATAAC-3 ¶.
To engineer HA-and Myc-tagged full-length ABCG2s (ABCG2  HA-F and  ABCG2   Myc-F   ), cDNA fragments encoding the HA-tagged and Myc-tagged  NH 2 termini were released from ABCG2  HA-NBD and ABCG2   Myc-TM1-4 constructs using BamHI and AocI double digestion. These fragments were then used to replace the corresponding wild-type full-length ABCG2 sequence without tags in pcDNA3 to generate ABCG2 HA-F and ABCG2
Myc-F . Cell culture and transfection. HEK293 cells were maintained at 37jC in 5% CO 2 in DMEM supplemented with 10% FCS. For transient transfections, cells at 90% confluency in 6-cm plate were transfected with 4 Ag desired constructs using LipofectAMINE/Opti-MEM reagents. To select stable clones, the transfected cells were grown in the presence of 0.8 mg/mL G418. The stable clones were maintained in 0.2 mg/mL G418. To establish stable clones with expression of two different constructs, the stable clones selected by G418 were cotransfected with 4 Ag pTK-Hyg, together with 20 Ag desired constructs followed by selection using 0.2 mg/mL hygromycin. The positive double stable cell lines were maintained in 0.2 mg/mL G418 and 0.1 mg/mL hygromycin.
Cell membrane and lysate preparations. Plasma membranes were prepared in exactly the same way as previously described (15, 16) , and the final membranes were resuspended in STBS [250 mmol/L sucrose, 150 mmol/L NaCl, 10 mmol/L Tris-HCl (pH, 7.5)]. For lysate preparation, cells at 90% confluency were harvested and lysed in ice-cold lysis buffer [150 mmol/L NaCl, 25 mmol/L Tris (pH, 7.4), 1 mmol/L EDTA, 2 mmol/L phenylmethylsulfonyl fluoride, and 1% Triton X-100]. After 30 min incubation at 4jC followed by brief sonication, the lysates were cleared by centrifugation at 16,000 Â g for 30 min. The protein concentrations of the membranes and lysates were determined using the Bio-Rad protein assay kit.
Immunoprecipitation. About 400 Ag cell lysates were diluted to 1.0 mL using the same lysis buffer (see above), then mixed with 10 AL normal mouse immunoglobulin G (IgG), and incubated for 2 h at 4jC, followed by addition of 40 AL Protein G-Sepharose beads and further incubation for 2 h at 4jC. The mixture was then centrifuged at 500 Â g for 1 min, the supernatants were transferred to fresh tubes and incubated with primary antibodies (anti-HA, anti-Myc, or control IgG, 1:100 dilution) for z3 h at 4jC. The reaction was centrifuged again at top speed for 15 min at 4jC, and the supernatants were transferred to fresh tubes and mixed with 40 AL Protein G-Sepharose beads and incubated overnight at 4jC with shaking. The immunoprecipitates were collected by centrifugation, washed five times with 1 mL lysis buffer each, and finally solubilized in 40 AL SDS sample buffer for Western blot analyses as previously described (15) .
Immunofluorescence staining and confocal imaging. This experiment was done as previously described (17) . Briefly, 5 Â 10 5 cells were cultured for 2 days, washed twice with PBS, fixed with 0.5 mL prechilled acetone/methanol (50:50, v/v) at room temperature for 10 min, and then blocked with ice-cold washing buffer (1% bovine serum albumin in PBS) for 30 min, followed by staining with anti-Myc antibody at 1:50 dilution for 1 h on ice. The cells were then washed twice with ice-cold washing buffer and incubated with FITC-conjugated anti-mouse IgG at 1:100 dilution, together with propidium iodide at 1:200 dilution for 1 h on ice. The staining was imaged using a Zeiss confocal microscope.
PFO-PAGE, nondenaturing PAGE, gel filtration chromatography, chemical cross-linking, and metabolic labeling. These experiments were done in exactly the same way as previously described (15) . The stoichiometry of the heterocomplex was calculated using the following formula: Mr complex = N Myc-TM5-6 Â Mr Myc-TM5-6 + N HA-F Â Mr HA-F and N Myc-TM5-6 + N HA-F = 12, where Mr represents apparent molecular weight, and N represents the numbers of subunits in the heterocomplex.
Drug efflux assay. Drug efflux assay was done as described previously (18) with PBS, resuspended in 0.5 mL PBS containing 20 Amol/L mitoxantrone, and incubated at 37jC for 30 min. Cells were then collected by centrifugation, washed twice with PBS, and resuspended in 0.5 mL PBS and incubated at 37jC for 1 h. The cells were then washed twice with PBS and analyzed by flow cytometry using a Becton Dickinson FACScalibur. The data were analyzed using Cell Quest Pro (BD Biosciences). In the negative vehicle controls, equal volumes of ethanol, which were used to dissolve mitoxantrone, were used.
Cytotoxicity assay. The cytotoxicity was measured using MTT and colony formation assays. MTT assay was done as previously described (19) using different concentrations of mitoxantrone and VP-16. EC 50 is defined as the concentration of drugs required to kill 50% of the cells in the control condition without any drugs. Relative resistance factors were determined by dividing median EC 50 of stable clones with expression of ABCG2
Myc-TM5-6 (TM5-6/Vec.), ABCG2
HA-F (Vec./HA-F), or both (TM5-6/HA-F) by that of cell clones transfected with vectors only (Vec./Vec.). Colony formation assay was done as described by Cheung et al. (20) 
Results
The ABCG2 oligomerization domain is located within the domain consisting of TM5-loop-TM6. To map the oligomeriza- Myc-F , respectively. Lysates from these cells were first tested for coexpression of the full-length and half ABCG2 molecules using Western blot analysis. All constructs were well expressed in HEK293 cells (Fig. 1B) . However, ABCG2
TMD-HA seemed to be smaller than the expected size likely due to its high hydrophobicity. To rule out the possibility that the observed smaller size of ABCG2 TMD-HA was due to truncation or internal translation initiation, we engineered and tested another construct double tagged with Myc and HA at its amino and carboxyl termini, respectively (Fig. 1A) . As shown in Fig. 1C , the double-tagged TMD had similar mobility as the original HA-tagged TMD. Thus, the smaller observed size of TMD is not due to internal initiation or Figure 2 . Localization of ABCG2 oligomerization domain to TM5-loop-TM6. A, schematic structure of tagged full-length and deletion constructs. The symbol representations are the same as in Fig. 1A truncation. It is possible that more SDS is bound to the TMD due to its higher hydrophobicity, which would cause a faster mobility of the TMD on SDS-PAGE. We next did coimmunoprecipitation and Western blot analyses of lysates from cells coexpressing full-length and domain constructs of ABCG2 using monoclonal anti-HA and anti-Myc antibodies. As shown in Fig. 1D and E, ABCG2
Myc-NBD did not coimmunoprecipitate ABCG2
HA-F (Fig. 1D) , whereas ABCG2
TMD-HA coimmunoprecipitated ABCG2 Myc-F (Fig. 1E) . Thus, it is likely that the oligomerization domain of ABCG2 is located within the TMD but not in the NBD.
To further map the oligomerization domain, we engineered two Myc-tagged constructs with sequential deletions of TM segments (ABCG2 Myc-TM1-4 with residues M 1 -V 536 and ABCG2 Myc-TM1-2 with M 1 -T 482 ; Fig. 2A ; see also Fig. 1A ). These constructs, together with ABCG2
Myc-F as a control, were transiently transfected into HEK293 cells with stable expression of ABCG2 HA-F . Western blot analyses of cell lysates (Fig. 2B ) and immunofluorescence staining of whole cells (Fig. 2C) were done to ensure the coexpression and proper trafficking to membranes of the truncated ABCG2s, respectively. It is noteworthy that ABCG2
Myc-TM1-4 and ABCG2 Myc-TM1-2 have similar apparent mobility on SDS-PAGE despite the fact that they have a difference of 54 amino acids in length. This may be again due to the fact that the additional 54 amino acids (TM3 and TM4) at the carboxyl terminus of ABCG2
Myc-TM1-4 (see Fig. 2A ) are mostly hydrophobic residues, which may cause increased mobility and a smaller apparent molecular weight than its true size, similar to the one observed with TMD discussed above in Fig. 1 . The use of high concentration gel may also contribute to the less clear difference between the two proteins. We next did coimmunoprecipitation and Western blot analyses with anti-HA and anti-Myc antibodies. As shown in Fig. 2D, ABCG2 Myc-F coprecipitated ABCG2 HA-F and Myc-TM5-6 expression were extracted using 1% SDS (top ) or 0.5% PFO (bottom ), and the extract was separated by gel filtration chromatography using Superdex column followed by TCA precipitation, SDS-PAGE, and Western blot analyses. The markers used were also treated and separated the same way and detected by a UV detector. The size of ABCG2
Myc-TM5-6 was estimated based on linear regression of protein markers: TG, thyroglobulin (669 kDa); BSA, bovine serum albumin (67 kDa); OA, ovalbumin (43 kDa); CT, chymotrypsinogen A (25 kDa); RA, RNase A (14 kDa); AU, arbitrary unit. B, PFO-and nondenaturing PAGE. Membranes (50 Ag) from HEK293 cells with stable ABCG2
Myc-TM5-6 expression were extracted using 0.5% PFO or 1% Triton X-100 and then separated by PFO-(lane 1 ) or nondenaturing PAGE (lane 2 ), followed by Western blot analysis. C, chemical cross-linking. HEK293 cells with stable ABCG2
Myc-TM5-6 expression were first treated without (À) or with (+) 2 mmol/L DSS, and crude membranes were isolated for SDS-PAGE and Western blot analyses. The size of ABCG2
Myc-TM5-6 was estimated based on linear regression of the protein markers used. D, coimmunoprecipitation. HEK293 cells with stable ABCG2
Myc-TM5-6 expression were metabolically labeled with [
35 S]methionine, followed by immunoprecipitation of lysate with anti-Myc or control IgG, separation on SDS-PAGE, and autoradiography to detect coprecipitated proteins. Myc antibody was used in all Western blot analyses.
vice versa as expected, whereas neither ABCG2
Myc-TM1-4 nor ABCG2 Myc-TM1-2 coprecipitated ABCG2
HA-F , suggesting that deletion of the domain consisting of TM5-loop-TM6 may have removed the oligomerization activity. It is thus possible that the oligomerization domain of human ABCG2 is located within TM5-loop-TM6.
To test this possibility, we engineered another truncated ABCG2 construct encoding only TM5-loop-TM6 (residues A 528 -S 655 ) with a Myc tag (ABCG2 Myc-TM5-6 ; Fig. 2A , also see Fig. 1A ) and did similar experiments as described above. Figure 2B and C shows that ABCG2
Myc-TM5-6 could be successfully coexpressed with ABCG2
HA-F and properly trafficked onto plasma membranes, respectively. ABCG2 Myc-TM5-6 could also coprecipitate ABCG2 HA-F and vice versa (Fig. 2D) . Thus, it is likely that the oligomerization domain of human ABCG2 is located within TM5-loop-TM6.
The TM5-loop-TM6 domain can form a homododecamer. To further determine if this domain indeed has oligomerization activity, we analyzed if it can form a homo-oligomer and estimated the number of subunits within the oligomer. For this purpose, a stable cell line overexpressing ABCG2
Myc-TM5-6 was established and subjected to several biochemical analyses to determine its native size.
Gel filtration chromatography (Superdex) was first employed to determine the oligomeric status of human ABCG2
Myc-TM5-6 following extraction from isolated plasma membranes with 0.5% PFO or 1% SDS as a control as previously described (15) . The eluted fractions from gel filtration were trichloroacetic acid (TCA) precipitated, separated by SDS-PAGE, and followed by Western blot to detect ABCG2
Myc-TM5-6 . We found that ABCG2
Myc-TM5-6 extracted by SDS was eluted in the fractions with retention volume of 12 to 13.5 mL with an estimated average molecular weight of f19 kDa (Fig. 3A, top ; Table 1 ), close to that determined by SDS-PAGE ( Fig. 3C and D and Table 1 ). ABCG2 Myc-TM5-6 extracted by PFO was eluted mainly in the fraction of a retention volume of f9 mL with an estimated molecular weight of f261 kDa (Fig. 3A , bottom; Table 1 ). Assuming that ABCG2
Myc-TM5-6 in SDS behaves as a monomer, the native ABCG2
Myc-TM5-6 in the peak fraction extracted by PFO is likely a dodecamer as we previously found for the full-length ABCG2 (15) .
We next used PFO-PAGE followed by Western blot to detect ABCG2
Myc-TM5-6 . This method has been used successfully in the past for studying several membrane proteins, including native ABCG2 (15, (21) (22) (23) (24) . As shown in Fig. 3B (lane 1) , ABCG2
Myc-TM5-6 extracted from isolated membranes using 0.5% PFO migrated as a broad band on PFO-PAGE, with an estimated average molecular weight of f226 kDa (Table 1) . We also did a nondenaturing PAGE and Western blot analysis of ABCG2
Myc-TM5-6 extracted by nonionic detergent Triton X-100 to rule out the potential problem with the use of PFO. As shown in Fig. 3B (lane 2) , ABCG2
Myc-TM5-6 again migrated mainly with a mobility of f235 kDa ( Table 1 ). Given that ABCG2
Myc-TM5-6 in SDS has an apparent molecular weight of f19 kDa in gel filtration and f17 kDa on SDS-PAGE (see Table 1 ), ABCG2
Myc-TM5-6 separated by PFO-and nondenaturing PAGE likely represents dodecameric complexes. It should also be noted that isolated plasma membranes were used in the above studies, and the findings confirm our conclusion that ABCG2
Myc-TM5-6 is located on plasma membranes.
To further determine whether the dodecameric ABCG2
Myc-TM5-6
exists in live cells, we conducted a chemical cross-linking experiment of live cells using DSS as previously described (15) . Membranes were then isolated and subjected to SDS-PAGE and Western blot analysis to detect ABCG2 Myc-TM5-6 . As shown in Fig. 3C , at least five cross-linked products were detected by anti-Myc antibody. The estimated molecular weights of these products are 179, 94, 62, 41, and 32 kDa, which likely correspond to dodecameric, hexameric, tetrameric, trimeric, and dimeric ABCG2
Myc-TM5-6 , respectively (see Table 1 ). The un-cross-linked monomeric ABCG2
Myc-TM5-6 has an apparent molecular weight of f17 kDa on SDS-PAGE (Fig. 3C) . It should be noted that the minor lower monomeric band (possibly a degradation product, see Discussion) disappeared following cross-linking. It is possible that it became undetectable following cross-linking due to its relatively low abundance and conversion to cross-linked molecules.
To test whether the oligomeric ABCG2 Myc-TM5-6 is homogeneous, we did immunoprecipitation assay following metabolic labeling with [
35 S]methionine of the cells with stable expression of ABCG2
Myc-TM5-6 and lysis of cells with Triton X-100. As shown in Fig. 3D , no additional proteins were coprecipitated with ABCG2
Myc-TM5-6 , suggesting that ABCG2 Myc-TM5-6 is likely a homooligomer.
Coexpression of the TM5-loop-TM6 domain inhibits ABCG2 functions. As shown above, ABCG2
Myc-TM5-6 is expressed on plasma membranes, contains the oligomerization domain, and can interact with the full-length ABCG2. It is of interest to determine if ABCG2
Myc-TM5-6 inhibits ABCG2 function by interacting with the full-length ABCG2 and competing for oligomerization. We first tested if coexpression of ABCG2
Myc-TM5-6 inhibits ABCG2-mediated drug resistance. For this purpose, stable cell clones expressing both 
1% Triton X-100 148 9.9
x Dodecamer 1% SDS 15 1.0
x Monomer *The size used for calculation is 19 kDa determined from gel filtration chromatography in SDS using Superdex. cThe size used for calculation is 17 kDa determined from SDS-PAGE without the use of DSS. bThis cross-linked product has an estimated size of 179 kDa based on linear regression analysis of molecular weight markers, although it seemed to migrate slightly slower than the 182-kDa marker on the gel (see Fig. 3D ).
x The size used for calculation is 15 kDa determined from gel filtration chromatography in SDS using Superose. Myc-TM5-6 and ABCG2 HA-F and vector control clones were first established using double selection as described in Materials and Methods. Figure 4A shows the expression of ABCG2 Myc-TM5-6 and ABCG2
HA-F , together or alone with vector controls as determined by Western blot analysis. We next did drug resistance analysis using MTT assay with anticancer drugs mitoxantrone and VP-16. As shown in Fig. 4B , the cells expressing ABCG2
HA-F alone (Vec./HA-F) are significantly more resistant to both drugs tested than the cells transfected with vector controls alone (Vec./Vec.) or cells expressing only ABCG2
Myc-TM5-6 (TM5-6/Vec.). However, the resistance to these drugs due to ABCG2
HA-F expression was significantly decreased by coexpressing ABCG2
Myc-TM5-6 (TM5-6/ HA-F). These observations were further confirmed when colony formation assay was used. As shown in Fig. 4C , coexpression of
ABCG2
Myc-TM5-6 significantly reduced the number of colonies formed by the resistant cells (Vec./HA-F) in the presence of anticancer drugs mitoxantrone or VP-16.
To determine if the inhibition of drug resistance by ABCG2
was due to its effect on ABCG2-mediated drug efflux, we employed the established fluorescence-activated cell sorting (FACS) analysis for mitoxantrone efflux. We first transiently transfected 2 Ag of the untagged full-length ABCG2 (ABCG2 F ) into HEK293 cells with stable expression of ABCG2
Myc-TM5-6 , followed by testing the drug efflux activity of the transiently transfected ABCG2 F 48 h after transfection. Figure 5A shows the expression of ABCG2
Myc-TM5-6 and ABCG2 F together or alone and control cells transfected with vectors as determined by Western blot analyses. Figure 5B shows typical profiles of mitoxantrone efflux in these cells as determined by FACS. As expected, the cells harboring vectors alone (Vec./Vec.) or expressing only ABCG2 Myc-TM5-6 (TM5-6/Vec.) have the highest level of mitoxantrone accumulation (less effluxed), whereas the cells expressing only ABCG2 F (Vec./F) have the lowest level of drug accumulation (more effluxed). Interestingly, the cells expressing both ABCG2
Myc-TM5-6 and ABCG2 F (TM5-6/F) have intermediate levels of mitoxantrone accumulation, suggesting that the mitoxantrone efflux activity of ABCG2 F has been tampered by coexpressing ABCG2
Myc-TM5-6 , and thereby, the cells have more drugs accumulated compared with the cells expressing only ABCG2
F . We also did another negative control experiment using ABCG2
Myc-TM1-4 and found that it, similar to the vector, had no effect on ABCG2 Fmediated mitoxantrone efflux (data not shown). Thus, most likely, the effect of ABCG2
Myc-TM5-6 on ABCG2 F -mediated drug efflux is due to its direct interaction with the full-length ABCG2.
We next conducted an assay using cells transiently transfected with different amounts of ABCG2 F cDNA into stable clones expressing ABCG2
Myc-TM5-6 to determine the dose response by elevating the ABCG2 F expression level. We did not perform the transient transfection of ABCG2
Myc-TM5-6 into cells with stable expression of ABCG2 F because of concerns that the efficiency of transient transfection of ABCG2
Myc-TM5-6 would be low, and many cells that have the stable expression of ABCG2 F would not have been transfected by ABCG2
Myc-TM5-6 and, thus, affecting the outcome and interpretation. On the other hand, transfecting ABCG2 F into cells with stable expression of ABCG2
Myc-TM5-6 will help ensure every cell that has ABCG2 F will also have ABCG2 . Figure 5C shows the differential expression of ABCG2 F in stable clones harboring vector control (lane 1) or ABCG2
Myc-TM5-6 (lanes 2-4). Figure 5D shows that 10 Ag ABCG2 F -transfected cells in the presence of ABCG2
Myc-TM5-6 [TM5-6/F(10)] had only the same level of efflux activity compared with the 2-Ag ABCG2 F -transfected cells in the absence of ABCG2
Myc-TM5-6 [Vec/F(2)], although the former had f3-fold ABCG2 F , suggesting that the efflux activity of ABCG2 F was severely inhibited by coexpressing ABCG2
Myc-TM5-6 . Hence, we conclude that the domain consisting of TM5-loop-TM6 can inhibit the drug efflux and resistance function of ABCG2, and that this inhibition is likely dose-dependent.
TM5-loop-TM6 domain competes for oligomerization with full-length ABCG2. We have shown above that the coexpression of the TM5-loop-TM6 domain inhibits the function of ABCG2 (Figs. 4  and 5) , and that it interacts with ABCG2 by coimmunoprecipitation (Fig. 3) . To further determine if the coexpression of TM5-loop-TM6 domain affects the homo-oligomerization of full-length ABCG2, we characterized hetero-oligomers in the stable cell clone that coexpresses both ABCG2
Myc-TM5-6 and ABCG2 HA-F using gel filtration chromatography (Superose) as described previously (15) . Myc-TM5-6 on drug resistance of full-length ABCG2. HEK293 cells with stable expression of both ABCG2
Myc-TM5-6 and ABCG2
HA-F together (Myc-TM5-6/HA-F ) or alone (Myc-TM5-6/Vec. and Vec./ HA-F ) and control vectors (Vec./Vec .) were subjected to Western blot analyses of lysates for expression (A ), MTT assay for relative resistance factors to mitoxantrone and VP-16 (B), and colony formation assay (C ).
Discussion
ABCG2 is an important drug efflux pump causing drug resistance when overexpressed in cancer cells. It has been suggested that ABCG2 exists as a homodimer and possibly as a homododecamer. However, the oligomerization domain remained elusive. In this study, we have successfully mapped the oligomerization domain of ABCG2 to TM5-loop-TM6 (ABCG2 Myc-TM5-6 ) and showed that ABCG2
Myc-TM5-6 alone can form a homododecamer, and it can inhibit the drug efflux and resistance function of human ABCG2.
Although each method generated slightly different results, the estimated size of domain ABCG2
Myc-TM5-6 complex was very large (148-261 kDa; see Table 1 ), and the complex was estimated to consist of 10 to 14 subunits calculated based on the size of monomeric proteins determined in each respective method. The highest oligomeric form that can be chemically cross-linked had an apparent size of f179 kDa. Considering that the oligomeric ABCG2
Myc-TM5-6 seemed to be homogeneous (Fig. 3D) and that the size determination by these methods is only an estimate, we conclude that the ABCG2
Myc-TM5-6 may be a homododecamer consisting of 12 ABCG2
Myc-TM5-6 subunits. This conclusion further supports that human ABCG2 is likely a homododecamer and confirms that the interactions between ABCG2 subunits are likely located within the domain containing TM5-loop-TM6.
We also observed that ABCG2 Myc-TM5-6 seems to be a doublet on SDS-PAGE in most cases, especially when expressed alone (see Fig. 6D ). The doublet disappears in other cases, especially when it is coexpressed with the full-length ABCG2 (see Fig. 6C ). The reason for these differences is currently unknown. It is, however, possible that the oligomerization with the full-length molecule may help the maturation and stabilization of ABCG2
Myc-TM5-6 . Recently, the intermolecular disulfide bond of ABCG2 has been localized to the extracellular loop (Cys 603 ) linking TM5 and TM6 (13, 14) , suggesting that this loop is likely involved in intersubunit interactions. Our finding, that the domain including TM5-loop-TM6 contains oligomerization activity, is consistent with these previous observations. However, because the intermolecular disulfide bond is only for the dimeric formation as previously shown (13, 14) , the finding that ABCG2
Myc-TM5-6 could form a homododecamer suggests that the domain containing TM5-loop-TM6 is likely also involved in other types of noncovalent proteinprotein interactions. Indeed, it has recently been found that a Gly residue (G 553 ) in TM5 is potentially involved in ABCG2 oligomerization (26) .
The GXXXG motif in transmembrane segments has been shown responsible for oligomerization of membrane proteins (27, 28) , and such a motif has been found in TM1, but not in TM5 and TM6, of ABCG2. However, removal of this motif in TM1 by site-directed mutagenesis did not abolish oligomerization of ABCG2, suggesting that the GXXXG motif in TM1 does not play an essential role in ABCG2 oligomerization (29) . This conclusion is supported by our current finding that the truncated ABCG2 containing TM1 to TM4 (ABCG2 Myc-TM1-4 ) did not contain an oligomerization domain (Fig. 2) .
Several other motifs, such as AXXXA, AXXXG, GXXXXXXG, and QXXS, have been suggested to involve interactions between membrane proteins (28, 30, 31) . Examination of the sequence of the domain containing TM5-loop-TM6 of human ABCG2 revealed that they contain only the QXXS motif (Q 569 YFS) in the loop linking TM5 and TM6. This sequence is completely conserved between the human and mouse ABCG2s. Examination of other members of the ABCG subfamily showed that human ABCG1 (Q 594 WMS) and ABCG4 (Q 563 WSS) and mouse ABCG1 (Q 583 WMS) and ABCG4 (Q 563 WSS) all have the QXXS motif in their loops linking TM5 and TM6. However, human ABCG5 and ABCG8 were found to have only Q 568 KYCS and Q 607 FS in their loops linking TM5 and TM6, although both have been shown to form heterodimers (32) . Whether the QXXS motif is involved in oligomerization of ABCG2 and other ABCG subfamily members and whether the semiconserved motif Q 568 KYCS and Q 607 FS in ABCG5 and ABCG8 are important for their heterodimerization await further investigations.
We also found that ABCG2 Myc-TM5-6 has an inhibitory effect on the function of the full-length human ABCG2 in both drug resistance and efflux. This effect may be due to the incorporation of ABCG2
Myc-TM5-6 into the complex by competing for ABCG2 F subunits. This finding also suggests that the oligomerization of ABCG2 may be used as a target to develop therapeutics for treating drug-resistant human cancers. Small molecules that mimic the oligomerization domain and are able to disrupt oligomerization of ABCG2 may be developed as therapeutics in the future to circumvent ABCG2-mediated drug resistance in cancer treatment.
